Idiotype-specific cytotoxic T lymphocytes in multiple myeloma: Evidence for their capacity to lyse autologous primary tumor cells

Blood

Volumn 97, Issue 6, 2001, Pages 1750-1755

  Wen, Yue Jin ^a   Barlogie, Bart ^a   Yi, Qing ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREFELDIN A; CONCANAMYCIN A; GAMMA INTERFERON; IMMUNOGLOBULIN IDIOTYPE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PERFORIN; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN PRESENTING CELL; ARTICLE; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; HUMAN; HUMAN CELL; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MULTIPLE MYELOMA; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION;

EID: 0035869383     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.6.1750     Document Type: Article

References (35)

1. The treatment of multiple myeloma
2. Plasma cell myeloma
3. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma
4. Relapse of multiple myeloma after autologous transplantation: Survival after salvage therapy
5. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression
6. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: Definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes
7. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma - Long-term results of a clinical trial
8. Cancer vaccines based on the identification of genes encoding cancer regression antigens
9. Transfer of myeloma idiotype-specific immunity from an actively immunized marrow donor
10. Modulation of anti-idiotypic immune response by immunization with the autologous M-component protein in multiple myeloma patients
11. Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses
12. Idiotypic protein-pulsed adherent peripheral blood mononuclear cell-derived dendritic cells prime immune system in multiple myeloma
13. Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma
14. Idiotypic vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma: A feasibility study
15. The dendritic cell system and its role in immunogenicity
16. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α
17. Concanamycin A, a powerful tool for characterization and estimation of contribution of perforin- and Fas-based lytic pathways in cell-mediated cytotoxicity
18. T-cell stimulation induced by idiotypes on monoclonal immunoglobulins in patients with monoclonal gammopathies
19. Idiotype-reactive T-cell subsets and tumor load in monoclonal gammopathies
20. The expanding universe of T-cell subsets: Th1, Th2 and more
21. T-cell subsets and cytokines in parasitic infections
22. Diagnostic criteria of multiple myeloma
23. Processing and presentation of idiotypes to MHC-restricted T cells
24. Anti-tumor activity of idiotype-specific, MHC-restricted Th1 and Th2 clones in vitro and in vivo
25. + T cells in tumor resistance against major histocompatibility complex class II molecule negative plasmacytoma cells
26. Anti-idiotypic T-cell activation in multiple myeloma induced by M-component fragments presented by dendritic cells
27. + subsets
28. Immunogenicity and cross-reactivity with idiotypic IgA of VH CDR3 peptide in multiple myeloma
29. T-cell epitope mapping of the idiotypic monoclonal IgG heavy and light chains in multiple myeloma
30. Myeloma bone marrow plasma cells: Evidence for their capacity as antigen-presenting cells
31. Fas and perfonn pathways as major mechanisms of T cell-mediated cytotoxicity
32. Two distinct pathways of specific killing revealed by perforin mutant cytotoxic T lymphocytes
33. Myeloma-reactive allospecific cytotoxic T lymphocytes lyse target cells by the granule exocytosis pathway
34. Mutation in the Fas antigen in patients with multiple myeloma
35. Selection for drug resistance results in resistance to Fas-mediated apoptosis